Update Your ProfileAcademic Title:
Assistant Professor
Primary Appointment:
Microbiology and Immunology
Additional Title:
Assistant Professor
Location:
UMB BioPark 1, 317
Phone (Primary):
410-706-8175
Fax:
410-706-8121
Education and Training
Russian State Medical University, MD, 1985
Gamaleya Scientific Research Institute of Epidemiology and Microbiology, PhD, 1994
Mayo Clinic and Foundation, Fellowship, Immunology, 2002
Biosketch
Svetlana Chapoval, MD, PhD is interested in asthma and cancer immunology. Her current research focuses on neuroimmune semaphorins 4A and 4D as novel regulators and therapeutic targets in allergic asthma.
Dr. Chapoval completed her postdoctoral training under a mentorship of Dr. Chella David in the Department of Immunology at Mayo Clinic in Rochester, MN. Her research was aimed to delineate the association of the HLA Class II polymorphism with allergic asthma susceptibility. Subsequently, she joined the faculty of the Department of Pulmonary and Critical Care Medicine at Yale University as an Associate Research Scientist.
While at Yale, Dr. Chapoval participated in several collaborative projects defining the roles of selected Th cytokines and growth factors in cellular and molecular mechanisms underlying chronic inflammatory lung diseases. She joined the Department of Microbiology and Immunology of the University of Maryland School of Medicine in 2006 as an Assistant Professor with a research position at the Center for Vascular and Inflammatory Diseases. She is a member of the Program in Oncology at the Greenebaum Comprehensive Cancer Center.
Dr. Chapoval serves as an Associate Editor for Frontiers in Immunology and PlosOne. She was a member of four NIH/NIAID scientific review groups.
Research/Clinical Keywords
Immunology, Immunotherapy, Semaphorins 4A and 4D, Plexins, Neuropilins, Asthma, Cancer, Gene-targeted mice, Biomarkers, T cell immunity, Treg cells, Dendritic cells
Highlighted Publications
Chapoval SP, Gao H, Fanaroff R, Keegan AD. (2024). Plexin B1 controls Treg numbers, limits allergic airway inflammation, and regulates mucins. Frontiers in Immunology, 14:1297354.
Scotland BL, Dharmaraj S, Cottingham AL, Truong N, Chapoval SP, Keegan AD, Pearson RM. (2024). Impact of antigen loading in tolerogenic nanoparticles to mitigate Th2-mediated allergic lung inflammation. Drug Delivery and Translational Research, 14(10):2930-2944.
Chapoval SP, Lee M, Lemmer A, Ajayi O, Qi X, Neuwald AF, Keegan AD. (2022). Identifying Function Determining Residues in Neuroimmune Semaphorin 4A. International Journal of Molecular Sciences, 23(6):3024.
Fink MY, Qi X, Shirey KA, Fanaroff R, Chapoval S, Viscardi RM, Vogel SN, Keegan AD. (2022). Mice Expressing Cosegregating Single Nucleotide Polymorphisms (D298G and N397I) in TLR4 Have Enhanced Responses to House Dust Mite Allergen. The Journal of Immunology, 208(9):2085-2097.
Chapoval SP, Hritzo M, Qi X, Tamagnone L, Golding A, Keegan AD. (2019) Semaphorin 4A stabilizes human Treg cell phenotype via Plexin B1. ImmunoHorizons, 3:71-87.
Additional Publication Citations
Research Interests
My current research focuses on neuroimmune semaphorins 4A and 4D as immune checkpoints and critical regulators of chronic inflammation as observed in asthma or cancer. My group was first to report that these two Class IV semaphorin molecules play opposite roles in allergic asthma severity; Sema4A inhibited the disease whereas Sema4D potentiated its manifestation. We are in the process of developing Sema4A- and 4D-based immunotherapeutic strategies aimed at manipulation of their receptor-binding potentials. Another collaborative research project I am involved in Dr. Keegan’s laboratory examines the mechanisms of asthma exacerbation by respiratory syncytial virus with a focus on virus-activated long-lived M2-type macrophages.